Table 1 Clinicopathological characteristics of patients
From: Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
Training set (n=96) | Validation set (n=27) | |
|---|---|---|
Baseline clinicopathological characteristic | ||
Age, no. (%) | ||
<70 years | 90 (93.8%) | 25 (92.6%) |
⩾70 years | 6 (6.2%) | 2 (7.4%) |
Sex, no. (%) | ||
Male | 73 (76.0%) | 23 (85.2%) |
Female | 23 (24.0%) | 4 (14.8%) |
PS, no. (%) | ||
ECOG PS 0 or 1 | 91 (94.8%) | 25 (92.6%) |
ECOG PS 2 or 3 | 5 (5.2%) | 2 (7.4%) |
Histological type, no. (%) | ||
Lauren’s intestinal | 40 (41.7%) | 9 (33.3%) |
Lauren’s diffuse | 56 (58.3%) | 18 (66.6%) |
Location of primary lesion, no. (%) | ||
Upper 1/3 | 14 (14.6%) | 2 (7.4%) |
Middle 1/3 | 28 (29.2%) | 10 (37.0%) |
Lower 1/3 | 49 (51.0%) | 15 (55.6%) |
Entire stomach | 5 (5.2%) | 0 |
Distant metastasis, no. (%) | 96 (100%) | 27 (100%) |
Tumor cell percentage in sample (%) | ||
Median | 60 | 70 |
Interquartile range | 50–70 | 55–80 |
Treatment and outcome | ||
Chemotherapy regimen, no. (%) | ||
Cisplatin/fluorouracil | 96 (100%) | 22 (81.5%) |
Cisplatin/capecitabine | 0 (0%) | 5 (18.5%) |
Relative dose intensity (%) | ||
Median | 79 | 81 |
Interquartile range | 73–88 | 72–87 |
Number of chemotherapy cycles | ||
Median | 4 | 7 |
Interquartile range | 3–9 | 5–13 |
Response (WHO criteria), no. (%) | ||
PR | 38 (44.7%) | 12 (48.0%) |
SD | 19 (22.4%) | 9 (36.0%) |
PD | 28 (32.9%) | 4 (16.0%) |
Non-measurable disease | 11 | 2 |
Second-line chemotherapy, no. (%) | 69 (71.9%) | 19 (70.4%) |
Median follow-up for survivors (months) | 39.4 | 30.4 |
Overall survival (months) | ||
Median | 8.1 | 12.6 |
Interquartile range | 5.6–15.9 | 7.4–30.4 |
Time to progression (months) | ||
Median | 3.9 | 6.3 |
Interquartile range | 2.2–8.3 | 3.9–14.6 |
